Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD). This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to...
Gespeichert in:
Veröffentlicht in: | Diabetes care 2017-12, Vol.40 (12), p.1733-1738 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1738 |
---|---|
container_issue | 12 |
container_start_page | 1733 |
container_title | Diabetes care |
container_volume | 40 |
creator | Buckley, Leo F Dixon, Dave L Wohlford, 4th, George F Wijesinghe, Dayanjan S Baker, William L Van Tassell, Benjamin W |
description | We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD).
This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM.
The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (
< 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96;
= 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93;
= 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%;
= 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (
> 0.62).
Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors. |
doi_str_mv | 10.2337/dc17-1366 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1943285098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1943285098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-49ceb30874de5f78da638ccd3960d0a41182d49239f8b85d31c0060ab2de572d3</originalsourceid><addsrcrecordid>eNpd0E9LwzAYx_EgipvTg29AAl70UM3fNjludepA3NimNylpkkpH18ykFXz3dm568PRcPvx4-AJwjtENoTS5NRonEaZxfAD6WFIecc7EIegjzGTEpSQ9cBLCCiHEmBDHoEeEZAmPZR-8TerG1qH8tPDV-tAGuGhUbZQ3cFQ5Z-DM2xBab2Hq6sa7CpY1XMzmk-dlNK7K9zKvLJwp35S63Ki6CdAVcJim0_ldNJqdgqNCVcGe7e8AvNyPl-lj9DR9mKTDp0hTxpqISW1zikTCjOVFIoyKqdDaUBkjgxTDWBDDJKGyELnghmKNUIxUTjqfEEMH4Gq3u_Huo7WhydZl0LaqVG1dGzIsGSWCIyk6evmPrlzr6-67TgmcyJj9qOud0t6F4G2RbXy5Vv4rwyjbNs-2zbNt885e7BfbfG3Nn_yNTL8BGTt55Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1981796498</pqid></control><display><type>article</type><title>Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Buckley, Leo F ; Dixon, Dave L ; Wohlford, 4th, George F ; Wijesinghe, Dayanjan S ; Baker, William L ; Van Tassell, Benjamin W</creator><creatorcontrib>Buckley, Leo F ; Dixon, Dave L ; Wohlford, 4th, George F ; Wijesinghe, Dayanjan S ; Baker, William L ; Van Tassell, Benjamin W</creatorcontrib><description>We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD).
This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM.
The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (
< 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96;
= 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93;
= 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%;
= 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (
> 0.62).
Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc17-1366</identifier><identifier>PMID: 28947569</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Aged ; Antihypertensive Agents - therapeutic use ; Blood pressure ; Blood Pressure - drug effects ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular system ; Cerebral infarction ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - mortality ; Female ; Hazards ; Health hazards ; Health risks ; Heart diseases ; Heart Failure - etiology ; Heart Failure - mortality ; Heart Failure - prevention & control ; Humans ; Hypertension - drug therapy ; Hypertension - mortality ; Male ; Middle Aged ; Myocardial infarction ; Myocardial Infarction - etiology ; Myocardial Infarction - mortality ; Myocardial Infarction - prevention & control ; Pressure effects ; Proportional Hazards Models ; Regression analysis ; Regression models ; Research design ; Risk analysis ; Risk Factors ; Risk management ; Stroke - etiology ; Stroke - mortality ; Stroke - prevention & control ; Treatment Outcome</subject><ispartof>Diabetes care, 2017-12, Vol.40 (12), p.1733-1738</ispartof><rights>2017 by the American Diabetes Association.</rights><rights>Copyright American Diabetes Association Dec 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-49ceb30874de5f78da638ccd3960d0a41182d49239f8b85d31c0060ab2de572d3</citedby><cites>FETCH-LOGICAL-c344t-49ceb30874de5f78da638ccd3960d0a41182d49239f8b85d31c0060ab2de572d3</cites><orcidid>0000-0003-0688-4487</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28947569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buckley, Leo F</creatorcontrib><creatorcontrib>Dixon, Dave L</creatorcontrib><creatorcontrib>Wohlford, 4th, George F</creatorcontrib><creatorcontrib>Wijesinghe, Dayanjan S</creatorcontrib><creatorcontrib>Baker, William L</creatorcontrib><creatorcontrib>Van Tassell, Benjamin W</creatorcontrib><title>Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD).
This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM.
The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (
< 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96;
= 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93;
= 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%;
= 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (
> 0.62).
Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.</description><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular system</subject><subject>Cerebral infarction</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - mortality</subject><subject>Female</subject><subject>Hazards</subject><subject>Health hazards</subject><subject>Health risks</subject><subject>Heart diseases</subject><subject>Heart Failure - etiology</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - prevention & control</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Pressure effects</subject><subject>Proportional Hazards Models</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Research design</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Risk management</subject><subject>Stroke - etiology</subject><subject>Stroke - mortality</subject><subject>Stroke - prevention & control</subject><subject>Treatment Outcome</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0E9LwzAYx_EgipvTg29AAl70UM3fNjludepA3NimNylpkkpH18ykFXz3dm568PRcPvx4-AJwjtENoTS5NRonEaZxfAD6WFIecc7EIegjzGTEpSQ9cBLCCiHEmBDHoEeEZAmPZR-8TerG1qH8tPDV-tAGuGhUbZQ3cFQ5Z-DM2xBab2Hq6sa7CpY1XMzmk-dlNK7K9zKvLJwp35S63Ki6CdAVcJim0_ldNJqdgqNCVcGe7e8AvNyPl-lj9DR9mKTDp0hTxpqISW1zikTCjOVFIoyKqdDaUBkjgxTDWBDDJKGyELnghmKNUIxUTjqfEEMH4Gq3u_Huo7WhydZl0LaqVG1dGzIsGSWCIyk6evmPrlzr6-67TgmcyJj9qOud0t6F4G2RbXy5Vv4rwyjbNs-2zbNt885e7BfbfG3Nn_yNTL8BGTt55Q</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Buckley, Leo F</creator><creator>Dixon, Dave L</creator><creator>Wohlford, 4th, George F</creator><creator>Wijesinghe, Dayanjan S</creator><creator>Baker, William L</creator><creator>Van Tassell, Benjamin W</creator><general>American Diabetes Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0688-4487</orcidid></search><sort><creationdate>20171201</creationdate><title>Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP</title><author>Buckley, Leo F ; Dixon, Dave L ; Wohlford, 4th, George F ; Wijesinghe, Dayanjan S ; Baker, William L ; Van Tassell, Benjamin W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-49ceb30874de5f78da638ccd3960d0a41182d49239f8b85d31c0060ab2de572d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular system</topic><topic>Cerebral infarction</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - mortality</topic><topic>Female</topic><topic>Hazards</topic><topic>Health hazards</topic><topic>Health risks</topic><topic>Heart diseases</topic><topic>Heart Failure - etiology</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - prevention & control</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Pressure effects</topic><topic>Proportional Hazards Models</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Research design</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Risk management</topic><topic>Stroke - etiology</topic><topic>Stroke - mortality</topic><topic>Stroke - prevention & control</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buckley, Leo F</creatorcontrib><creatorcontrib>Dixon, Dave L</creatorcontrib><creatorcontrib>Wohlford, 4th, George F</creatorcontrib><creatorcontrib>Wijesinghe, Dayanjan S</creatorcontrib><creatorcontrib>Baker, William L</creatorcontrib><creatorcontrib>Van Tassell, Benjamin W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buckley, Leo F</au><au>Dixon, Dave L</au><au>Wohlford, 4th, George F</au><au>Wijesinghe, Dayanjan S</au><au>Baker, William L</au><au>Van Tassell, Benjamin W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>40</volume><issue>12</issue><spage>1733</spage><epage>1738</epage><pages>1733-1738</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><abstract>We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD).
This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM.
The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (
< 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96;
= 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93;
= 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%;
= 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (
> 0.62).
Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>28947569</pmid><doi>10.2337/dc17-1366</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0688-4487</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-5992 |
ispartof | Diabetes care, 2017-12, Vol.40 (12), p.1733-1738 |
issn | 0149-5992 1935-5548 |
language | eng |
recordid | cdi_proquest_miscellaneous_1943285098 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Aged Antihypertensive Agents - therapeutic use Blood pressure Blood Pressure - drug effects Cardiovascular disease Cardiovascular diseases Cardiovascular system Cerebral infarction Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - mortality Female Hazards Health hazards Health risks Heart diseases Heart Failure - etiology Heart Failure - mortality Heart Failure - prevention & control Humans Hypertension - drug therapy Hypertension - mortality Male Middle Aged Myocardial infarction Myocardial Infarction - etiology Myocardial Infarction - mortality Myocardial Infarction - prevention & control Pressure effects Proportional Hazards Models Regression analysis Regression models Research design Risk analysis Risk Factors Risk management Stroke - etiology Stroke - mortality Stroke - prevention & control Treatment Outcome |
title | Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A40%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intensive%20Versus%20Standard%20Blood%20Pressure%20Control%20in%20SPRINT-Eligible%20Participants%20of%20ACCORD-BP&rft.jtitle=Diabetes%20care&rft.au=Buckley,%20Leo%20F&rft.date=2017-12-01&rft.volume=40&rft.issue=12&rft.spage=1733&rft.epage=1738&rft.pages=1733-1738&rft.issn=0149-5992&rft.eissn=1935-5548&rft_id=info:doi/10.2337/dc17-1366&rft_dat=%3Cproquest_cross%3E1943285098%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1981796498&rft_id=info:pmid/28947569&rfr_iscdi=true |